http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
-
NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease
-
NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
-
NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
-
NantKwest (NK) and NantCell Announce FDA Authorization for NANT Cancer Vaccine Clinical Trials
-
NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer
-
NantKwest (NK), Viracta Therapeutics Announce Series B Financing and Immunotherapy Pact
-
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
-
Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research
-
NantKwest (NK) Receives FDA Orphan Drug Designation for aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
-
NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
-
Imerys Carbonates is recognized for its sustainability commitment
-
NantKwest (NK), Altor BioScience Enter co-Development Agreement on IL-15, IL-2 Development
-
Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer
-
NantKwest (NK) Offers Update on Three Clinical Programs at BofA Conference
-
NantKwest Provides Update on Clinical Programs at Bank of America Healthcare Conference Multiple Immunotherapy Combinations Announced as Part of Cancer Moonshot 2020 Initiative
-
Cancer MoonShot 2020 Milestone: National MoonShot IRB Established with Schulman IRB to Provide Central Review Services for National Immunotherapy Coalition (NIC) Clinical Trials
-
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against NantKwest, Inc., and Strongly Encourages Investors with Losses to Contact the Firm
-
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims against NantKwest, Inc. And Strongly Encourages Investors With losses To Contact The Firm
-
Nant Leaders to Share Vision of Cancer MoonShot 2020 Program at Premier Oncology Event
-
NantKwest to Host Investor Day on January 14, 2016
-
NantKwest Added to Nasdaq Biotechnology Index
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
-
NantKwest Announces Presentation of Preclinical Data of HER2.taNK at the San Antonio Breast Cancer Symposium (SABCS)
-
NantKwest Names Angela Wilson Chief Financial Officer
-
NantKwest Announces $50 Million Stock Repurchase Program
-
NantKwest Announces Presentations at Upcoming Investment Conference Meetings
-
Notable Analyst Rating Changes 10/28: (TWTR) (AAPL) (MAS) Upgraded; (FIVE) (MRVL) (SBLK) Downgraded
-
NantKwest Inc. (Nasdaq: NK) to Ring The Nasdaq Stock Market Closing Bell
-
NantKwest Inc. (Nasdaq: NK) to Ring The Nasdaq Stock Market Closing Bell

